Status:
COMPLETED
Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects
Lead Sponsor:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study is designed to look at the safety aspects and effects of repeat inhaled doses of GW597901X in asthmatics to develop this drug for its use in asthma and Chronic Obstructive Pulmonary Disease...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Subjects with mild to moderate stable asthma but no other lung problems.
- Male subjects or female subjects who are not able to get pregnant (e.g. post-menopausal or surgically sterile).
- Non-Smokers.
- Subjects who show a measurable improvement in the function of their lungs after a single dose of salbutamol.
- Exclusion criteria:
- Any significant illness.
- Subjects with heart problems.
- Subjects who have a cold or chest infection 2-4 weeks prior to the study or have life-threatening asthma.
- Subjects who take medication for their asthma, or other conditions, not compatible with this study.
- Subjects who are over sensitive to salbutamol or to ipratropium.
Exclusion
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00354042
Start Date
August 1 2004
Last Update
May 18 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.